Fibromyalgia: Remedee Labs is developing an endorphin stimulator

This is a step forward for people suffering from fibromyalgia. The French start-up Remedee Labs specializing in the management of this disease has received the designation of “innovative device” from the American health agency (FDA) for its endorphin stimulator.

This designation speeds up the time to market for this type of device. It would also allow Remedee Labs to enter the US market. “Breakthrough Device status for our endorphin boosting solution is a major milestone that recognizes the potential of our device in managing the pain of fibromyalgia patients. We look forward to working closely with the FDA so that we can bring our solution to American patients as quickly as possible.” said David Crouzier, co-founder and CEO of Remedee Labs, in a press release.

Stimulate endorphins to relieve pain

No less than 14 million people in Europe are affected by fibromyalgia. Worldwide, 2% of the population is affected by this syndrome, which causes joint pain of moderate to severe intensity as well as fatigue and sleep disturbances. For the first time, a drug-free approach has been found by Remedee Labs to treat these symptoms. The principle ? Stimulate the patient’s endorphins by millimeter waves using a connected bracelet.

It is by combining medical research, micro and nanotechnologies that the first endorphin stimulator by millimeter waves intended for individual use could be designed. This new approach to treating pain involves releasing endorphins, which are the body’s natural pain relievers, quickly and effectively. According to the first results, users declaring themselves to suffer from fibromyalgia have observed a significant improvement in their life as well as their sleep.

A study in France on 170 fibromyalgia patients has been ongoing since 2021 and the results are expected to be published in 2023.